Health Canada approves BeiGene's Brukinsa for marginal zone lymphoma
Health Canada has granted marketing approval to BeiGene’s Brukinsa to treat marginal zone lymphoma (R/R MZL) in adult individuals.
Source: pharmaceutical-technology.com
Stay updated with breaking news from Librepath Wikipedia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Health Canada has granted marketing approval to BeiGene’s Brukinsa to treat marginal zone lymphoma (R/R MZL) in adult individuals.